Ipamorelin FAERS Safety Signals: What the Post-Market Data Actually Shows

What Is Ipamorelin and Why Does Its Regulatory Status Matter for Safety?

Ipamorelin is a synthetic pentapeptide GHSR-1a agonist. It does not have an FDA-approved new drug application, which means there is no agency-reviewed prescribing label, no mandatory pharmacovigilance program, and no post-market safety obligation tied to a sponsor. Every safety signal discussed below is therefore derived from voluntary reporting systems, animal studies, and small human trials conducted before commercial compounding became widespread.

The Absence of an Approved Label Is Not a Minor Detail

Without an approved NDA, the FDA has no authority to compel ipamorelin manufacturers or prescribers to file MedWatch reports. The entire post-market safety picture depends on clinicians and patients voluntarily entering data into FAERS. That structural gap shapes every conclusion in this article.

The FDA's FAERS database accepts reports from patients, practitioners, and manufacturers for any substance, including unapproved compounds. A FAERS search for "ipamorelin" returns a small number of case reports relative to approved GH-axis drugs like somatropin. That low count likely reflects under-reporting rather than a genuinely clean safety record. The FDA itself acknowledges that FAERS "cannot be used to calculate the incidence of an adverse event" because the denominator (total exposed patients) is unknown for compounded substances. [1]

How Compounding Pharmacy Rules Affect Oversight

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, licensed compounding pharmacies may prepare individualized prescriptions for patients using bulk drug substances on the FDA's 503A list. [2] Ipamorelin appeared on the FDA's category 1 list of bulk substances nominated for compounding, but the agency's 2023 proposed rule moved it toward evaluation for removal, citing a lack of clinical evidence meeting the statutory standard of "a clinical need that cannot be met by an approved drug." [3] Removal from the 503A list would make compounding of ipamorelin unlawful for most pharmacies, substantially altering how practitioners access the drug.

What FAERS Reports Reveal About Ipamorelin Adverse Events

FAERS data for ipamorelin is sparse by any standard. The database's publicly downloadable quarterly extracts (available at fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers) list ipamorelin as a suspect or concomitant substance in fewer than 100 case reports as of the most recent quarterly export. [1] By contrast, somatropin (approved recombinant GH) carries tens of thousands of FAERS entries.

Reported Signal Categories

The adverse event terms appearing most frequently in ipamorelin FAERS entries cluster into four categories:

• Injection-site reactions. Pain, erythema, and induration at the subcutaneous injection site. These are consistent with the peptide's physical properties and the mechanics of subcutaneous delivery, not with any receptor-mediated toxicity.
• Vasomotor effects. Transient facial flushing and warmth within 30 minutes of injection. Raun et al. Noted that ipamorelin, unlike GHRP-6, produces minimal release of prolactin and ACTH in rats even at doses 200-fold above the GH-releasing ED50, which may explain why vasomotor effects tend to be mild and self-limited. [4]
• Fluid retention. Mild peripheral edema and weight gain, consistent with the known effect of elevated IGF-1 on renal sodium reabsorption. [5]
• Headache. Reported in a minority of cases, likely secondary to transient shifts in intracranial pressure associated with GH axis stimulation.

Signal Strength and Disproportionality Analysis

Disproportionality statistics (reporting odds ratios, proportional reporting ratios) in FAERS are calculated against the entire database background. Because ipamorelin has so few reports, no statistically stable disproportionality signal can be extracted. The FDA Sentinel System, which analyzes electronic health records and insurance claims from over 100 million patients, does not cover unapproved compounded peptides in its standard distributed queries. [6] That means the standard pharmacovigilance infrastructure that catches safety signals for approved drugs is largely blind to ipamorelin.

HealthRX Post-Market Surveillance Framework for Compounded Peptides (No Approved NDA)

When evaluating a compounded peptide with no NDA, clinicians should weight safety signals in this order:

1. Mechanistic predictions from receptor pharmacology (highest reliability for on-target effects).
2. Animal dose-escalation toxicology data.
3. Small human trials with IGF-1 and cortisol endpoints.
4. FAERS voluntary case reports (lowest reliability; use for hypothesis generation only).
5. Emerging FDA Sentinel queries if and when the agency expands coverage.

The Raun et al. 1998 Study: The Foundational Safety Reference

The most-cited primary safety reference for ipamorelin remains Raun et al., published in the European Journal of Endocrinology in 1998. [4] The study characterized ipamorelin's selectivity for GH release in male Sprague-Dawley rats compared with GHRP-2 and GHRP-6 across a dose range spanning the ED50 to 500x the ED50.

Key Findings Relevant to Safety

At 500x the GH-releasing ED50, ipamorelin produced no statistically significant increase in ACTH or cortisol compared with vehicle control. GHRP-6 at the same relative dose raised plasma ACTH by approximately 3-fold (P<0.01 vs. Vehicle). This selectivity profile is the pharmacological basis for the clinical claim that ipamorelin has a "cleaner" safety profile than older GHRPs. [4]

Prolactin elevation was also absent with ipamorelin at all tested doses. The authors concluded that "ipamorelin is the first GHRP receptor agonist with a selectivity for GH release similar to that displayed by GHRH." [4]

The critical limitation: this study used rats, not humans, and doses were given as single IV boluses. Chronic subcutaneous dosing in humans, particularly at the 200-300 mcg two-to-three-times-daily regimens used in compounding practice, has not been evaluated in a controlled, powered clinical trial.

What the Study Does Not Address

Raun et al. Did not evaluate:

• Long-term IGF-1 elevation and downstream cancer risk.
• Tachyphylaxis with daily dosing over 6 to 12 months.
• Drug interactions with insulin, thyroid hormone, or sex steroids (common co-prescriptions in TRT and HRT contexts).
• Effects in patients with pre-existing pituitary adenomas.

IGF-1 Elevation: The Downstream Safety Signal Requiring Monitoring

GH secretagogues raise IGF-1. That mechanism is the therapeutic intent, but sustained IGF-1 elevation above the age-adjusted reference range carries theoretical oncologic risk. The epidemiological literature on IGF-1 and cancer risk is not uniformly alarming, but it is not exculpatory either.

IGF-1 and Cancer Epidemiology

A meta-analysis published in The Lancet Oncology (Key et al.) found a statistically significant association between circulating IGF-1 levels in the top versus bottom quartile and risk of premenopausal breast cancer (OR 1.65, 95% CI 1.26 to 2.08) and colorectal cancer in both sexes. [7] That association does not prove that pharmacologically raising IGF-1 from a low baseline to a mid-normal range causes cancer. The association was observed in observational data spanning endogenous IGF-1 variation. The question of whether exogenous GH secretagogue use alters cancer risk has not been answered in a randomized trial.

The FDA's approved prescribing information for somatropin (Genotropin, Norditropin) includes a warning against use in patients with active malignancy and advises monitoring IGF-1 to avoid supraphysiologic levels. [8] That same caution applies logically to ipamorelin, even though no equivalent label exists for the compounded peptide.

Practical IGF-1 Monitoring Thresholds

Most endocrinology guidelines recommend keeping IGF-1 within the age- and sex-matched reference range during GH axis therapy. The Endocrine Society's 2011 clinical practice guideline on adult GH deficiency states that "IGF-1 should be maintained in the age-normalized reference range" and that values persistently above the upper limit of normal should prompt dose reduction. [9] Applying that standard to ipamorelin is rational even in the absence of ipamorelin-specific guidance.

Cortisol and HPA Axis: Separating Animal Data from Clinical Reality

Animal Evidence for HPA Selectivity

As described above, Raun et al. Demonstrated HPA axis sparing at supratherapeutic doses in rats. [4] That finding has been replicated in a secondary publication examining ipamorelin analogs, though head-to-head human data comparing HPA responses to ipamorelin versus other GHRPs remains absent from the peer-reviewed literature.

Clinical Observations in Compounding Practice

Clinicians prescribing ipamorelin through 503A pharmacies generally report that morning cortisol and ACTH values remain stable during 3 to 6-month courses at 200-300 mcg subcutaneous doses. No randomized clinical trial has confirmed this observation with pre-registered outcomes. The absence of evidence is not evidence of absence, particularly given FAERS under-reporting rates.

The FDA Sentinel System's capacity to detect HPA suppression from a compounded peptide is essentially zero under current data-sharing agreements. [6] That gap means any cortisol signal would need to come from either spontaneous FAERS reports or a prospective registry, neither of which currently exists for ipamorelin.

FDA Regulatory Actions Affecting Ipamorelin Access and Safety Oversight

The 503A Bulk Substances List and Proposed Removal

The FDA published a proposed rule in 2023 (Docket FDA-2019-N-5043) that would remove ipamorelin from the list of bulk drug substances that may be used in compounding under Section 503A. [3] The agency's reasoning: ipamorelin does not meet the statutory criteria because it has not been shown, via adequate and well-controlled clinical investigations, to be safe and effective for any condition. The proposed rule does not allege imminent harm; it applies the standard of evidence required for any bulk substance to remain on the list.

If finalized, this rule would remove the legal basis for most 503A compounding of ipamorelin. Patients currently using compounded ipamorelin should discuss this regulatory trajectory with their prescribing clinician.

503B Outsourcing Facilities

Section 503B outsourcing facilities operate under different rules and may compound drugs not on the 503A list, subject to FDA inspection and cGMP requirements. [2] Whether ipamorelin could remain available through 503B outsourcers after a final 503A rule is a legal and regulatory question that will depend on the final rule language and any litigation.

No EMA EPAR Exists

The European Medicines Agency (EMA) has not issued a European Public Assessment Report (EPAR) for ipamorelin. No EU member state has granted marketing authorization. This means the EMA pharmacovigilance database (EudraVigilance) contains no systematic adverse event data tied to a marketing authorization holder, mirroring the FAERS gap in the United States.

What Prescribers Should Document to Contribute to the Safety Record

Because spontaneous reporting is the only active surveillance mechanism for ipamorelin, every prescriber who observes an adverse event has an obligation to file a MedWatch report. The FDA's MedWatch Online Voluntary Reporting Form is available at fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program. [10]

Minimum Documentation for a Useful FAERS Report

A useful report includes:

• Exact dose, route, and frequency of ipamorelin.
• Lot number and compounding pharmacy name (if available).
• All concomitant medications, particularly other peptides, testosterone, thyroid hormone, and insulin.
• Baseline and on-treatment IGF-1 levels with collection dates.
• Time from first dose to adverse event onset.

Reports missing dose and concomitant medication data are categorized as "incomplete" by FDA reviewers and contribute less to signal detection than complete submissions. [1]

Pre-Prescription Lab Panel

Before initiating ipamorelin, the following baseline labs allow for structured safety monitoring and contribute meaningful data if an adverse event occurs:

• IGF-1 (age- and sex-matched reference range).
• Morning cortisol (8:00 a.m. Fasting draw).
• Fasting glucose and HbA1c (GH elevation can worsen insulin resistance).
• CBC, CMP (renal and hepatic clearance baseline).

Repeat IGF-1 and fasting glucose at 6 weeks, then every 3 months. If IGF-1 exceeds the upper limit of the age-matched reference range on two consecutive draws, reduce the dose before continuing therapy.

Ipamorelin vs. Other GH Secretagogues: Comparative Safety Context

Ipamorelin is not the only compounded GH secretagogue in clinical use. GHRP-2, GHRP-6, sermorelin, and CJC-1295 are also prescribed through 503A pharmacies. Each has a distinct safety profile worth comparing briefly.

GHRP-6 and GHRP-2: Broader Hormonal Stimulation

GHRP-6 raises ghrelin-mediated appetite significantly and stimulates cortisol and prolactin at high doses. [4] GHRP-2 produces stronger GH pulses but also raises cortisol more reliably than ipamorelin at equivalent GH-releasing doses. The Raun et al. Selectivity data place ipamorelin favorably relative to both. [4]

Sermorelin: The Only Compounded GH-Axis Peptide With Prior Approval History

Sermorelin (GHRH 1-29) held an FDA-approved indication for GH deficiency diagnosis before the NDA was voluntarily withdrawn by the manufacturer in 2002. [8] That prior approval means sermorelin has more historical clinical trial data and a longer human safety record than ipamorelin. Prescribers choosing between sermorelin and ipamorelin based on safety-signal transparency should weigh that difference.

CJC-1295 DAC: Extended Half-Life, Distinct Risk Profile

CJC-1295 with drug affinity complex (DAC) has a half-life of approximately 8 days versus ipamorelin's 2 hours. Longer GH stimulation means longer IGF-1 elevation and a larger window for potential adverse effects if dosing needs to be interrupted due to a side effect. No FAERS signal for CJC-1295 DAC is substantially more developed than the ipamorelin signal.